Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Fr J Urol ; 34(2): 102571, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38717459

ABSTRACT

PURPOSE: To report on the oncological outcomes of active surveillance (AS) in low-grade prostate cancer (PCa) patients using the French SurACaP protocol, with a focus on long-term outcomes. METHODS: This multicenter study recruited patients with low-grade PCa between 2007 and 2013 in four referral centers in France. The cohort included patients meeting the SurACaP inclusion criteria, i.e., aged ≤75years, with low-grade PCa (i.e., ISUP 1), clinical stage T1c/T2a, PSA ≤10ng/mL and ≤3 positive cores and tumor length ≤3mm per core. The SurACaP protocol included a digital rectal examination every six months, PSA level measurement every three months for the first two years after inclusion and twice a year thereafter, a confirmatory biopsy in the first year after inclusion, and then follow-up biopsy every two years or if disease progression was suspected. Multiparametric magnetic resonance imaging (mpMRI) was progressively included over the study period. RESULTS: A total of 86 consecutive patients were included, with a median follow-up of 10.6 years. Only one patient developed metastases and died of PCa. The estimated rates of grade reclassification and treatment-free survival at 15 years were 53.4% and 21.2%, respectively. A negative mpMRI at baseline and a negative confirmatory biopsy were significantly associated with a lower risk of disease progression (P<0.05). CONCLUSIONS: AS using the French SurACaP protocol is a safe and valuable strategy for patients with low-risk PCa, with excellent oncological outcomes after more than 10 years' follow-up. Future studies are crucial to broaden the inclusion criteria and develop a personalized, risk based AS protocol with the aim of de-escalating follow-up examinations. LEVEL OF EVIDENCE: Grade 4.


Subject(s)
Neoplasm Grading , Prostatic Neoplasms , Watchful Waiting , Humans , Prostatic Neoplasms/pathology , Prostatic Neoplasms/diagnosis , Male , Middle Aged , Aged , Follow-Up Studies , France/epidemiology , Time Factors , Prostate-Specific Antigen/blood , Disease Progression , Digital Rectal Examination , Neoplasm Staging
2.
Fr J Urol ; 34(1): 102537, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37783635

ABSTRACT

PURPOSE: To report the long-term oncological outcomes of active surveillance (AS) in selected patients with favorable intermediate-risk (IR) prostate cancer (PCa). METHODS: A retrospective database review of two academic centers was conducted to identify favorable IR PCa patients initially managed by AS between 2014 and 2022. Favorable IR PCa was defined by the presence of one single element of IR disease (i.e., PSA 10-20ng/mL, Gleason Grade Group [GG] 2, or cT2b). All patients were diagnosed and followed up according to a contemporary scheme, including MRI and image-guided biopsies. The primary endpoint was metastasis-free survival. RESULTS: A total of 57 patients met our inclusion criteria and the median follow-up was 56months. During follow-up, there were no cases of metastasis or death due to PCa, but 6 deaths due to competing causes. A total of 25 (44%) and 6 patients (11%) had definitive treatment and GG 3 reclassification during follow-up, respectively. In multivariable Cox hazard regression analysis, the risk of undergoing definitive treatment was significantly associated with PSA density>0.15 (HR: 4.82, 95% CI: 1.47 to 15; P=0.01) and PI-RADS 4-5 lesions on mpMRI (HR: 2.48, 95% CI: 1.06 to 5.19; P=0.006). Interestingly, tumor burden (P=0.3) and GG (P=0.7) on biopsy were not associated with definitive treatment. CONCLUSIONS: AS is a safe and valuable strategy for well-selected patients with favorable IR prostate cancer, with excellent oncological outcomes after five years' follow-up.


Subject(s)
Prostate-Specific Antigen , Prostatic Neoplasms , Male , Humans , Prostatic Neoplasms/diagnosis , Magnetic Resonance Imaging , Retrospective Studies , Watchful Waiting , Image-Guided Biopsy
3.
J Intellect Disabil Res ; 68(2): 181-192, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37984471

ABSTRACT

BACKGROUND: Adolescents with disabilities have fewer opportunities to participate in community-based fitness programmes. The purpose of this study was to examine the impact of a school-based running programme at a local middle school in Lebanon, Pennsylvania, on fitness and quality of life (QoL) in children with physical and cognitive disabilities in a life-skills classroom. METHODS: Nineteen adolescents with diagnosed disabilities including intellectual disability (ID), autism spectrum disorder and Down syndrome were recruited from three life-skills classrooms to participate in a school-based running programme. The programme was designed to be implemented two times/week for 6 weeks by classroom teachers/aides. Physical therapy faculty and students developed the programme and assisted with implementation. Each session lasted 30 min, consisting of a warm-up and cooldown, relay races, games and timed runs. Pre- and post-test measures included physiological cost index (PCI) and Paediatric Quality of Life Inventory™ (PedsQL™). Pre- and post-test data were compared using Wilcoxon signed rank tests. Each week participants also completed a training log to reflect on the activity for the day. RESULTS: Participants demonstrated significant improvements in PCI (P = 0.028) and the PedsQL™ (P = 0.008) following the running programme. CONCLUSIONS: Results of this study suggest that participation in a 6-week school-based running programme may improve fitness and QoL in adolescents with disabilities.


Subject(s)
Autism Spectrum Disorder , Disabled Persons , Humans , Child , Adolescent , Quality of Life , Exercise , Schools , Physical Fitness
4.
Prog Urol ; 32(1): 47-52, 2022 Jan.
Article in French | MEDLINE | ID: mdl-34462169

ABSTRACT

INTRODUCTION: The information provided at the time of diagnosis of Non Muscle-Invasive Bladder Cancer (NMIBC) is highly variable. Well-informed patient are more involved in shared decisions. The objective of our study was to assess the information perceived by the patient at the time of NMIBC diagnosis and its impact on quality of life. METHODS: The VICAN french cohort involved a representative sample of 4174 cancer patients and 5 years survivors. Patients reported outcomes (PROs) were collected by phone and self-questionnaire. Among the 118 NMIBC patients, the term used to define the pathology at diagnosis was prospectively evaluated. The impact on quality of life (using SF-12, EORTC-QLQ-C30 and HAD scale) and on adherence to the care protocol (endoscopic monitoring) has been assessed. RESULTS: Only 26.8% of patients reported hearing the word « Cancer ¼ at the time of NMIBC diagnosis. Conversely, 73.2% of them reported others terms, including « Tumor ¼ (22%), « Polyp ¼ (24%), and « Carcinoma ¼ (17.1%). There was no difference in terms of physical, mental quality of life and anxiety, regardless of the term used. Adherence to the follow-up endoscopic protocol was better in the group of patients hearing the word "Cancer". CONCLUSION: Three quarters of patients treated for NMIBC did not integrate the concept of « Cancer ¼ at the time of diagnosis. Quality of life and anxiety did not differ significantly depending on the term used at diagnosis. However, adherence to care protocol appears to be higher when using the word "Cancer". LEVEL OF EVIDENCE: 3.


Subject(s)
Quality of Life , Urinary Bladder Neoplasms , Humans , Neoplasm Invasiveness , Patient Reported Outcome Measures , Prospective Studies , Surveys and Questionnaires
5.
Br J Anaesth ; 120(6): 1401-1411, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29793605

ABSTRACT

BACKGROUND: Cyclopropyl-methoxycarbonyl metomidate, or ABP-700, is a second generation analogue of etomidate, developed to retain etomidate's beneficial haemodynamic and respiratory profile but diminishing its suppression of the adrenocortical axis. The objective of this study was to characterise the safety and efficacy of 30-min continuous infusions of ABP-700, and to assess its effect on haemodynamics and the adrenocortical response in healthy human volunteers. METHODS: Five cohorts involving 40 subjects received increasing infusion doses of ABP-700, propofol 60 µg kg-1 min-1 or placebo. Safety was evaluated through adverse event (AE) monitoring, safety laboratory tests, and arterial blood gasses. Haemodynamic and respiratory stability were assessed by continuous monitoring. Adrenocortical function was analysed by adrenocorticotropic hormone (ACTH) stimulation tests. Clinical effect was measured using the modified observer's assessment of alertness/sedation (MOAA/S) and continuous bispectral index monitoring. RESULTS: No serious AEs were reported. Haemodynamic and respiratory effects included mild dose-dependent tachycardia, slightly elevated blood pressure, and no centrally mediated apnoea. Upon stimulation with ACTH, no adrenocortical depression was observed in any subject. Involuntary muscle movements (IMM) were reported, which were more extensive with higher dosing regimens. Higher dosages of ABP-700 were associated with deeper sedation and increased likelihood of sedation. Time to onset of clinical effect was variable throughout the cohorts and recovery was swift. CONCLUSIONS: Infusions of ABP-700 showed a dose-dependent hypnotic effect, and did not cause severe hypotension, severe respiratory depression, or adrenocortical suppression. The presentation and nature of IMM is a matter of concern. CLINICAL TRIAL REGISTRATION: NTR4735.


Subject(s)
Anesthetics, Intravenous/adverse effects , Etomidate/analogs & derivatives , Adolescent , Adrenal Cortex/drug effects , Adrenal Cortex/metabolism , Adult , Anesthetics, Intravenous/administration & dosage , Anesthetics, Intravenous/pharmacology , Blood Pressure/drug effects , Dose-Response Relationship, Drug , Etomidate/administration & dosage , Etomidate/adverse effects , Etomidate/pharmacology , Female , Healthy Volunteers , Heart Rate/drug effects , Humans , Infusions, Intravenous , Male , Middle Aged , Propofol/adverse effects , Propofol/pharmacology , Respiratory Mechanics/drug effects , Single-Blind Method , Young Adult
6.
Neuroscience ; 138(1): 123-32, 2006.
Article in English | MEDLINE | ID: mdl-16377091

ABSTRACT

During development of the neuromuscular junction, high densities of acetylcholine receptors accumulate beneath the overlying nerve terminal. A defining feature of mature synapses is the sharp demarcation of acetylcholine receptor density, which is approximately 1000-fold higher in the postsynaptic as compared with the contiguous extrasynaptic muscle membrane. These high densities of receptors accumulate by at least four mechanisms, re-distribution of existing surface receptors, local synthesis of new receptors, decreased turnover of synaptic receptors, and limitation of diffusion of sub-neural, aggregated receptors. The limitation of receptor diffusion within the membrane is likely in part due to the anchoring of acetylcholine receptor complexes to components of the cytoskeleton. Here we have tested the idea that lipid rafts--mobile, cholesterol enriched microdomains within the lipid bilayer--are another mechanism by which acetylcholine receptors are clustered in the postsynaptic apparatus. Using mouse C2C12 cells, a muscle cell line, we show that a carboxy terminal 95 amino acid fragment [C95 (4,8)] of the extracellular matrix molecule agrin that is essential for nerve-induced postsynaptic differentiation, promotes the redistribution of acetylcholine receptors into lipid rafts. Disruption of lipid rafts before agrin treatment largely inhibits de novo agrin-induced acetylcholine receptor clustering. Moreover, mature acetylcholine receptor clusters are destabilized if lipid rafts are disrupted. These results show that lipid rafts are important in both the initial clustering and later stabilization of agrin-induced acetylcholine receptor clusters and also suggest that lipid rafts may contribute to the postsynaptic localization of acetylcholine receptors in vivo.


Subject(s)
Agrin/chemistry , Membrane Microdomains/physiology , Receptors, Cholinergic/genetics , Animals , Cells, Cultured , Cholesterol/metabolism , Extracellular Matrix Proteins/metabolism , Mice , Microscopy, Confocal , Multigene Family , Neuromuscular Junction/physiology , Octoxynol
8.
Ophthalmology ; 106(10): 2033-7, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10519604

ABSTRACT

OBJECTIVE: To determine whether brimonidine 0.2% can control intraocular pressure (IOP) spikes as well as apraclonidine 1.0% can in those patients undergoing argon laser trabeculoplasty (ALT). DESIGN: Prospective, randomized, double-masked, clinical trial. PARTICIPANTS: A total of 56 eyes of 41 patients with open-angle glaucoma or ocular hypertension were entered in the study; 46 eyes of 41 patients were eventually used for the final analysis. INTERVENTION: Patients were randomized to receive either brimonidine 0.2% or apraclonidine 1.0% before and after 360 degrees ALT. Both patient and physician were masked as to which agent each patient received. MAIN OUTCOME MEASURES: Intraocular pressure measurements were recorded before surgery and at 1, 2, and 4 hours after surgery. The difference between the preoperative IOP (baseline) and the highest recorded postoperative IOP was recorded as the maximum IOP change. The mean of the maximum IOP change for each group was analyzed using a two-sample, one-tailed t test. RESULTS: The mean of the maximum IOP change in the brimonidine 0.2% group was -2.6+/-3.6 mmHg, and the mean for the apraclonidine 1.0% group was -2.3+/-3.7 mmHg (P = 0.8). No patient had a pressure spike greater than 10 mmHg. CONCLUSIONS: Brimonidine 0.2% appears to be as effective as apraclonidine 1.0% in preventing IOP spikes after argon laser trabeculoplasty.


Subject(s)
Adrenergic alpha-Agonists/therapeutic use , Clonidine/analogs & derivatives , Intraocular Pressure/drug effects , Laser Therapy , Quinoxalines/therapeutic use , Trabeculectomy/methods , Adrenergic alpha-Agonists/administration & dosage , Aged , Brimonidine Tartrate , Clonidine/administration & dosage , Clonidine/therapeutic use , Double-Blind Method , Female , Glaucoma, Open-Angle/therapy , Humans , Male , Middle Aged , Ocular Hypertension/therapy , Ophthalmic Solutions/administration & dosage , Ophthalmic Solutions/therapeutic use , Prospective Studies , Quinoxalines/administration & dosage
9.
J Neurosci ; 18(15): 5891-900, 1998 Aug 01.
Article in English | MEDLINE | ID: mdl-9671676

ABSTRACT

The heat shock protein (HSP) 27 is constitutively expressed at low levels in medium-sized lumbar dorsal root ganglion (DRG) cells in adult rats. Transection of the sciatic nerve results in a ninefold upregulation of HSP27 mRNA and protein in axotomized neurons in the ipsilateral DRG at 48 hr, without equivalent changes in the mRNAs encoding HSP56, HSP60, HSP70, and HSP90. Dorsal rhizotomy, injuring the central axon of the DRG neuron, does not upregulate HSP27 mRNA levels. After peripheral axotomy, HSP27 mRNA and protein are present in small, medium, and large DRG neurons, and HSP27 protein is transported anterogradely, accumulating in the dorsal horn and dorsal columns of the spinal cord, where it persists for several months. Axotomized motor neurons also upregulate HSP27. Only a minority of cultured adult DRG neurons are HSP27-immunoreactive soon after dissociation, but all express HSP27 after 24 hr in culture with prominent label throughout the neuron, including the growth cone. HSP27 differs from most axonal injury-regulated and growth-associated genes, which are typically present at high levels in early development and downregulated on innervation of their targets, in that its mRNA is first detectable in the DRG late in development and only approaches adult levels by postnatal day 21. In non-neuronal cells, HSP27 has been shown to be involved both in actin filament dynamics and in protection against necrotic and apoptotic cell death. Therefore, its upregulation after adult peripheral nerve injury may both promote survival of the injured neurons and contribute to alterations in the cytoskeleton associated with axonal growth.


Subject(s)
Heat-Shock Proteins/physiology , Neurons, Afferent/physiology , RNA, Messenger/biosynthesis , Sciatic Nerve/injuries , Animals , Axotomy , Cells, Cultured , Heat-Shock Proteins/genetics , Male , Nerve Endings/metabolism , Neurons, Afferent/metabolism , Rats , Rats, Sprague-Dawley , Up-Regulation
10.
J Ocul Pharmacol Ther ; 14(1): 1-4, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9493778

ABSTRACT

To determine if pilocarpine 4% produces miosis when delivered via a spray, eleven eyes of ten patients undergoing a laser peripheral iridotomy for occludable angles were pretreated with one application of pilocarpine spray to closed eyelids. Standardized pupil photographs for pupil diameter measurements were taken before and thirty minutes after the spray. Contralateral eyes served as controls (9 eyes) All treated eyes achieved miosis. The mean pupil diameter in the treated group was 4.1+/-0.9 mm before the spray and 1.5+/-0.3 mm after the spray (p < 0.0001). The average change in pupil diameter in the treated group was 2.6+/-0.9 mm compared to 0.0+/-0.2 mm in the control eyes (p < 0.0001). Pilocarpine spray is an effective delivery modality for intraocular miosis.


Subject(s)
Miotics/administration & dosage , Pilocarpine/administration & dosage , Pupil/drug effects , Aerosols , Humans , Miosis/chemically induced , Nebulizers and Vaporizers , Pupil/physiology
11.
Article in English | MEDLINE | ID: mdl-9884623
12.
Mol Cell Neurosci ; 8(6): 377-88, 1997.
Article in English | MEDLINE | ID: mdl-9143556

ABSTRACT

During neuromuscular development, neuronal contact with peripheral targets is associated with an increase in synaptic vesicle protein (SVP) gene expression, suggesting that target contact and upregulation of SVP genes are causally related. To test this idea, we analyzed the developmental expression pattern of synaptotagmin (syt) mRNAs in the chick lateral motor column (LMC) using in situ hybridization. Syt I mRNA in the LMC is upregulated from Embryonic Day 4.5 (E4.5) to E5.5, coincident with the time these neurons begin to make contact with their muscle targets. In contrast, levels of mRNA for neurofilament do not change during this time. Extirpation of the limb bud prior to motor axon outgrowth eliminates the increase in syt I mRNA ipsilaterally. Later in development, there is a switch in syt isoform abundance in the LMC, with syt II mRNA being upregulated between E15 and E20 and syt I mRNA being downregulated. Our results suggest that contact with targets upregulates syt I gene expression during neuromuscular synapse formation in vivo, and that a later stage of synaptic maturation involves changes in SVP isoform abundance.


Subject(s)
Calcium-Binding Proteins , Gene Expression Regulation , Membrane Glycoproteins/genetics , Motor Neurons/physiology , Nerve Tissue Proteins/genetics , Spinal Cord/embryology , Animals , Chick Embryo/physiology , Embryonic and Fetal Development , Membrane Proteins/genetics , Neural Pathways/embryology , Neurofilament Proteins/genetics , RNA, Messenger/metabolism , Spinal Cord/cytology , Synaptotagmin II , Synaptotagmins
13.
Eur J Neurosci ; 9(11): 2269-83, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9464922

ABSTRACT

The synaptic protein agrin is required for aspects of both pre- and postsynaptic differentiation at neuromuscular junctions. Although a direct effect of agrin on postsynaptic differentiation, presumably through the MuSK receptor, is established, it is not clear whether agrin directly affects the presynaptic nerve. To provide evidence on this point, we used anti-agrin IgG to disrupt agrin function in chick ciliary ganglion (CG) neuron/myotube cocultures. In cocultures grown in the presence of 200 microg/ml anti-agrin IgG, clustering of acetylcholine receptors (AChRs), extracellular matrix proteins, and the synaptic vesicle protein synaptotagmin (syt) at nerve-muscle contacts was inhibited. Syt clustering was still inhibited in the presence of 100 microg/ml blocking antibody, while the postsynaptic clustering of AChRs, heparan sulphate proteoglycan, and s-laminin was retained. Additionally, in CG neurons cultured with COS cells expressing agrin A0B0, which lacks the ability to signal postsynaptic differentiation, syt clustering was induced and this clustering was also blocked by anti-agrin IgG. Our results demonstrate that agrin function is acutely required for pre- and postsynaptic differentiation in vitro, and strongly suggest that agrin is directly involved in the induction of presynaptic differentiation.


Subject(s)
Agrin/pharmacology , Neuromuscular Junction/drug effects , Synapses/drug effects , Animals , COS Cells , Cell Differentiation/drug effects , Cells, Cultured , Chick Embryo , Coculture Techniques , Fluorescent Antibody Technique, Indirect , Immunoglobulin Fab Fragments/isolation & purification , Immunoglobulin Fab Fragments/metabolism , Immunoglobulin G , Immunohistochemistry , Motor Neurons/drug effects , Nerve Tissue Proteins/biosynthesis , Recombinant Proteins/pharmacology , Transfection
14.
Neuron ; 15(6): 1365-74, 1995 Dec.
Article in English | MEDLINE | ID: mdl-8845159

ABSTRACT

Proteins of the synaptic basal lamina are important in directing the differentiation of motor nerve terminals. One synaptic basal lamina protein, agrin, which influences postsynaptic muscle differentiation, has been suggested to influence nerve terminals as well. To test this hypothesis, we cocultured chick ciliary ganglion neurons with agrin-expressing CHO cells. Ciliary ganglion neurons, but not sensory neurons, adhered five times as well to agrin-expressing cells as to untransfected cells. Further, ciliary ganglion neurites were growth inhibited upon contact with agrin-expressing cells. Finally, the synaptic vesicle protein synaptotagmin became concentrated at contacts between ciliary ganglion neurites and agrin-expressing cells. These activities were shared by neuronal and muscle-derived agrin isoforms, consistent with the hypothesis that muscle agrin may influence the presynaptic axon. Our results suggest that agrin influences the growth and differentiation of motoneurons in vivo.


Subject(s)
Agrin/physiology , Calcium-Binding Proteins , Motor Neurons/cytology , Motor Neurons/physiology , Animals , CHO Cells , Cell Adhesion , Cell Communication , Cell Differentiation/physiology , Cell Membrane/metabolism , Cricetinae , Ganglia, Parasympathetic/metabolism , Ganglia, Parasympathetic/ultrastructure , Membrane Glycoproteins/metabolism , Nerve Tissue Proteins/metabolism , Neurites/physiology , Synaptotagmins
15.
Ophthalmic Surg ; 26(1): 57-60, 1995.
Article in English | MEDLINE | ID: mdl-7746627

ABSTRACT

One hundred eyes of 100 patients in whom Tenon's cysts (TCs) developed in the early postoperative period following trabeculectomy with mitomycin C were retrospectively studied to determine their incidence, possible risk factors associated with their development, and the clinical course of the patients in whom they occurred. The incidence of TC formation was 29/100 (29%). Significantly more cysts developed in the men than in the women. There were no significant differences between those patients in whom TCs developed and those in whom they did not in terms of age, race, type of preoperative medications, mean preoperative intraocular pressure (IOP), prior argon laser trabeculoplasty, prior trabeculectomy, prior Tenon's cyst formation, or prior cataract surgery. The 29 patients in whom a Tenon's cyst developed had a mean follow up of 22.0 +/- 12.9 weeks, with a mean IOP at the last examination of 14.2 +/- 6.3 mm Hg (as compared with 20.7 +/- 8.3 mm Hg at the time of diagnosis). One patient required a repeat trabeculectomy with mitomycin C. Two patients required bleb needling, subsequent TC excision, and eventual seton placement. Of the remaining 26, 14 (54%) required no glaucoma medication for IOP control, 11 (42%) required one, and 1 (4%) required two.


Subject(s)
Conjunctival Diseases/etiology , Cysts/etiology , Glaucoma/therapy , Mitomycin/therapeutic use , Trabeculectomy/adverse effects , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Incidence , Intraocular Pressure , Male , Middle Aged , Retrospective Studies , Risk Factors
16.
Graefes Arch Clin Exp Ophthalmol ; 227(3): 201-5, 1989.
Article in English | MEDLINE | ID: mdl-2737478

ABSTRACT

We used a digital image processor to make multiple measurements from the fluorescein angiograms of 53 cases of central serous chorioretinopathy (CSC) associated with single leaks. We determined the area of the base of each serous detachment, the location of its geometric center (CM), the area of the RPE leak, the distance from the fovea to the leak, and the distance from the leak to the CM. The distribution of leaks across the base of the detachments was nonrandom (P less than 0.005) with leaks clustering near the centers of the detachments. When the leak was found within 1 disc diameter from the fovea, the center of the detachment was located virtually at the foveola, suggesting that the central macula is predisposed to the development of CSC. Detachments associated with "smokestack" leaks were significantly larger than those associated with round pinpoint leaks (P less than 0.02).


Subject(s)
Image Processing, Computer-Assisted , Retinal Detachment/pathology , Adult , Female , Fluorescein Angiography , Fovea Centralis/pathology , Humans , Male , Middle Aged , Photography , Radiography , Retinal Detachment/diagnostic imaging
17.
West J Med ; 139(3): 319-23, 1983 Sep.
Article in English | MEDLINE | ID: mdl-6636745

ABSTRACT

Lyme disease is a recently described clinical entity with cutaneous, neurologic, articular and cardiac manifestations. Since the original description of the disease in 1977, more than 500 cases have been reported. Although the vast majority of patients have been from the area near Lyme, Connecticut, we have seen four patients from northern California with various aspects of Lyme disease. This diagnosis should be considered in patients who have traveled to tick regions and who have a distinctive skin lesion (erythema chronicum migrans). Clinical and epidemiologic evidence suggests the disease is transmitted by a tick, lxodes dammini in the eastern United States, lxodes pacificus in the West and lxodes ricinus in Europe. The etiologic agent, a new spirochete, may have been recently discovered.


Subject(s)
Arthritis, Infectious/complications , Erythema/complications , Spirochaetales Infections/complications , Adult , Arachnid Vectors , Arthritis, Infectious/diagnosis , Arthritis, Infectious/therapy , California , Female , Humans , Male , Middle Aged , Space-Time Clustering , Spirochaetales Infections/etiology , Ticks
18.
Sante Ment Que ; 6(1): 19-29, 1981.
Article in French | MEDLINE | ID: mdl-17093713

ABSTRACT

Prevention in community mental health elaborates upon the necessary and sufficient causes of specific mental health centers in the community. The political-administration of research funds is an undesirable reality which becomes necessary if it is to obtain the resources in the community. The article clearly establishes the Catch. 22 logic of dollar-wise administrators who needs to forsee the cost-benefits that will accrue to the community from the work on prevention of mental illness. The fallacy of course, is that the prevention of mental illness or suicide has financial consequences and that there are of a nature to be assessed. Rather, the extent such benefits appear is dependent upon the choice of data one interprets and the instruments one uses to such ends. The experimental rigors seem inappropriate vis-à-vis the number of variables to be studied and manipulated. The ethical and moral considerations of experimentation, when someone's mental health is at stake, seems to outweigh the experimental paradigms.

19.
Biochim Biophys Acta ; 484(2): 375-85, 1977 Oct 13.
Article in English | MEDLINE | ID: mdl-20963

ABSTRACT

Phenylacetone, 4-phenyl-2-butanone, and 4-oxopentyltrimethylammonium chloride were tested as potential transition state analogs for eel acetylcholinesterase (acetylcholine hydrolase, EC 3.1.1.7). Phenylacetone is a competitive inhibitor of the enzyme but not a transition state analog, since its binding constant is similar to that for the substrate phenyl acetate. 4-Phenyl-2-butanone binds 6-18 times more tightly than the inhibitors 4-phenyl-2-butanol and N-benzylacetamide and the substrate benzyl acetate and also blocks inactivation of the enzyme with methanesulfonyl fluoride. However, its binding is independent of pH in the range 5-7.5, whereas both V and V/Km for benzyl acetate hydrolysis decrease with decreasing pH in this range. These data indicate a specific but weak interaction between the ketone carbonyl and the enzyme, but probably do not justify considering this compound a transition state analog. 4-oxopentyltrimethylammonium iodide has previously been shown to bind about 125 times more strongly than the substrate acetylcholamine. It also binds about 375 times more strongly than the alcohol 4-hydroxypentyltrimethylammonium iodide. Furthermore, the ketone protects the enzyme from inactivation by methansulfony fluoride, while the corresponding quaternary ammonium alcohol accelerates this inactivation reaction. This additional information confirms that the ketone is a transition state analog.


Subject(s)
Acetylcholinesterase/metabolism , Acetone/analogs & derivatives , Acetone/metabolism , Animals , Binding Sites , Binding, Competitive , Butanones/metabolism , Eels , Hydrogen-Ion Concentration , Ketones/metabolism , Kinetics , Mesylates , Quaternary Ammonium Compounds/metabolism , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...